Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kindred selects Kambi for NJ sports betting platform

Kindred has agreed with Kambi to extend its current agreement on sports betting products to also include New Jersey. The extension demonstrates the strong partnership between Kindred and Kambi.Kindred Group (previously Unibet Group) has agreed to sign an addendum to the current contract the Group has with Kambi. The addendum will give Kindred access to Kambi’s sports betting platform in New Jersey. This agreement, together with the already communicated agreement with SG Digital, will allow Kindred to offer customers in New Jersey a full range of first class sports betting and casino

Biotage acquires PhyNexus, Inc. and strengthens its position in lab-scale purification of biomolecules

Stockholm – Biotage AB (publ) (Biotage), (Nasdaq Stockholm: BIOT.ST) has today entered into an agreement to acquire all outstanding shares in the privately held company PhyNexus, Inc. (PhyNexus) based in California, US, for a total purchase price of approx. USD 21.5 million (corresponding to approx. SEK 195 million[1]) financed through a combination of newly issued shares in Biotage and existing cash at hand. The acquisition is expected to strengthen Biotage’s position as a separations company within the growing biomolecule arena. Biotage will be able to provide its global customers an

Raisio plc's renewed dividend policy

Raisio Oyj, Stock Exchange Release, 4.12.2018, 8.31 am. Finnish time RAISIO PLC’S RENEWED DIVIDEND POLICYThe Board of Directors has renewed the company’s dividend policy. Raisio plc aims to pay an annual dividend of 50 - 100 per cent of earnings per share (EPS) for its continuing operations. In addition, the Board of Directors may propose an extra dividend to be distributed. The payment of dividends under the dividend policy is subject to the condition that the payment does not compromise the company’s financial position or the achievement of strategic objectives. Raisio plc

Skanska invests EUR 24 M, about SEK 250 M, in the second phase of office project in Łódź, Poland

Skanska has invested EUR 24 M, about SEK 250 M, in the second phase of Brama Miasta, an office development in Łódź, Poland. The second phase with a total leasable area of around 13,600 square meters will consist of one building 15 stories high.Brama Miasta is Skanska’s third office development in Łódź. This two-building complex, to be delivered in two phases, will offer a total leasable area of around 41,400 square meters. The project is expected to receive LEED Gold certification, as well as a “Building without barriers” certificate. The new office development will be situated in the

Raisio's new strategy for 2019 - 2021

Raisio plc, Stock Exchange Release, 4 December 2018 at 8.30 am. Finnish time RAISIO’S NEW STRATEGY FOR 2019 - 2021 Raisio’s Board of Directors has approved the new strategy of the company for 2019 - 2021. Raisio focuses on healthy food and aims to be an innovative and increasingly international brand house. Strategic growth both organically and through acquisitions is Raisio’s key target. The goal-oriented Responsibility Programme is a solid part of the strategy. Raisio’s new Healthy Growth Strategy is based on two strong pillars. On the one hand, Raisio will continue to invest in

Handheld promotes Robert Broström to Director of Service and Support

[Lidköping, Sweden, December 4, 2018] Handheld Group , a leading manufacturer of rugged mobile computers has promoted Robert Broström to Director of Service and Support. Additionally, in an effort to further strengthen the Handheld customer experience and service quality, this function has been added to the Handheld management team. As Director of Service and Support, Robert Broström has global responsibility for the Handheld service and support departments  serving customers and resellers around the

Nordic Nanovector: Additional preclinical studies with CD37-targeting radioimmunotherapies for B-cell malignancies presented at ASH

Oslo, Norway, 4 December 2018 Nordic Nanovector ASA (OSE: NANO) notes that two new poster presentations from preclinical studies with CD37-targeting radioimmunotherapies were made at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018 in San Diego, CA, USA). These posters were presented in addition to the results of the Phase 1/2 trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma – see separate announcement. The posters are as follows: Abstract 4422 Abstract title:

Data presented at ASH support emapalumab as an innovative, targeted therapeutic option for primary HLH

Swedish Orphan Biovitrum AB (publ) (Sobi™)  and Novimmune SA  are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place 1-4 December 2018, in San Diego. “Primary HLH is an aggressive hyper-inflammatory syndrome that can quickly become fatal if not treated. This study demonstrated that emapalumab treatment induced rapid and sustained

Amendment of previously announced press release Sedana Medical AB (publ), Sedana Medical’s nomination committee appointed

In the previously announced press release the following text was included: This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on 3 December 2018 at 17:00 pm (CET). This text should not have been included and below is the amended press release in full.Press release December 03, 2018. Sedana Medical’s nomination committee appointed Sedana Medical AB (publ) today publish that in accordance with the resolution of

Axactor SE – Announcement regarding the relocation to Norway and potential trade restrictions for certain shares related thereto

Oslo, December 3, 2018 – As previously announced, Axactor SE (“Axactor” or the “Company”), have filed for relocation of its registered office from Sweden to Norway in order to reduce the burden of administrative expenses and achieve a more efficient group structure. The expected day for completion of the relocation is December 20, 2018 at which point, the Company will be removed out of the company register at the Sweden Companies Registration Office (Bolagsverket) and instead registered with the Norwegian Companies Register (Foretaksregisteret i Brønnøysund). As set-out in the

Borr Drilling Limited (BDRILL) – Purchase of own shares

Borr Drilling Limited (the “Company”) has today purchased 200,000 of its own shares at an average price of NOK 28.7281 per share. The share purchase has been carried out in connection with the share repurchase program announced by the Company on 28 August 2018. After this transaction the Company holds 5,898,572 of its own shares in treasury. 3 December 2018 Hamilton, Bermuda This information is subject to disclosure requirements pursuant to Sections 4-2 and 5-12 of the Norwegian Securities Trading Act.

Integrum collaborating with Chalmers to develop new artificial joint to restore wrist-like movements to forearm amputees

Mölndal 3 december 2018 A new artificial joint restores important wrist-like movements to forearm amputees, something which could dramatically improve their quality of life. A group of researchers led by Max Ortiz Catalan, Research Director at Integrum and Associate Professor at Chalmers University of Technology, Sweden, have published their research in the journal IEEE Transactions on Neural Systems & Rehabilitation Engineering.“Depending on the level of amputation, you could still have most of the biological actuators and sensors left for wrist rotation. These allow you to feel, for

DOMETIC ACQUIRES KAMPA, A FAST-GROWING PRODUCT INNOVATOR IN RETAIL AND AFTERMARKET

On December 3 2018, Dometic acquires Kampa, an innovative provider of Retail and Aftermarket products based in the UK. Kampa significantly broadens Dometic’s Retail and Aftermarket offering in EMEA, with good potential for further expansion and profitable growth.Summary · Dometic acquires Kampa, an innovative outdoor leisure company with focus on lightweight and inflatable awning room and tent technology with a leading position in the UK · The acquisition strengthens and expands Dometic's position in Retail and Aftermarket through new product areas, a broader distribution network

More from the Company Monthly Newsletter November 2018

During November, the focus has been on preparing our market introduction. In connection with Medica in Düsseldorf we met with potential distributors. We intensified our cooperation with our partners who will assemble our products, participated at the Sepsis Day in Malmö, conducted an extraordinary general meeting and signed a distribution agreement for the Baltic States.We met some suppliers and potential distributors for eight markets during Medica in Düsseldorf. We have met three of them before. The others we met for the first time as they are related to new markets.It saves both time

First Berlin Equity Research publishes updated independent analysis of Cyxone

Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent analysis report of Cyxone.The updated analysis was published on Monday, December 04, 2018, where First Berlin Equity Research has further taken into account the company's potential with a continued positive outcome. The report in English can be read in its entirety on the company's website. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0) 723 816 168Email: kjell.g.stenberg@cyxone.comAdelgatan 21221 22 MalmöSwedenwww.

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 3.12.2018

Fiskars Corporation  NOTIFICATION 3.12.2018 at 18:30 EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 3.12.2018 Date 3.12.2018Exchange transaction BuyShare class FSKRSAmount       1 500 Average price/share 15.8720  EUR  Highest price/share 15.9400 EUR Lowest price/share 15.8200 EUR Total price 23,808.00  EUR  The shares held by Fiskars Corporation on 3.12.2018: FSKRS 310,060  On behalf of Fiskars Corporation Skandinaviska Enskilda Banken AB (Publ) Antti Salakka   Janne Tiihonen

World’s leading sleep improvement platform Oura Health passes $20 million in funding

Oura Health is now shipping in over 100 countries, enabling more people to join the Oura communityToday Oura Health  announces that it has raised $20 million to date. Its latest investment round was led by MSD Capital  (Michael Dell) and joined by Steve Chen, the co-founder of YouTube , Kevin Lin, the co-founder of Twitch , Dave Morin, the founder of Sunrise , alongside the co-founders from Skype , Box.com (

Interim data from the ongoing HORIZON trial with melflufen presented in an oral presentation at the 60th American Society of Hematology Meeting

Stockholm – December 3, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Professor Paul G. Richardson presented updated interim data with melflufen (Ygalo®) from the ongoing HORIZON trial at the 60th ASH meeting in San Diego, California, USA.Overall conclusions The updated phase II data with melflufen in late-stage relapsed-refractory multiple myeloma patients refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) shows: · An Overall Response Rate (ORR) of 33%, in patients where 46% had

Total Voting Rights

3 December 2018 16:00 GMT Transparency Directive Voting Rights and Capital The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 November 2018 the issued share capital of AstraZeneca PLC with voting rights is 1,266,811,703 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,266,811,703. The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which

Intrum and Intesa Sanpaolo close strategic agreement to create market leading servicer of non-performing loans (NPL) in Italy

According to plan, Intrum and Intesa Sanpaolo have closed the agreement regarding the establishment of a market leading servicer of non-performing loans (NPLs) in Italy, which was signed on 17 April 2018.The servicing platform, Intrum Italy, is majority owned by Intrum with Intesa Sanpaolo retaining a 49% minority equity stake. Together with the establishment of the platform Intesa Sanpaolo divested a >€10bn nominal value NPL portfolio which Intrum has taken a 41% minority equity stake in and which will be serviced by Intrum Italy. The combined investment level for both parts of the

Sedana Medical’s nomination committee appointed

Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 22, 2018, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee.Sedana Medical's Nomination Committee for the 2019 Annual General Meeting consists of: ·  Thomas Eklund, Chairman of the Board ·  Sten Gibeck, Board

Ossur Hf : Transactions in relation to share buyback program

Announcement no. 69/2018 3 December 2018  Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 30 June 2019. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital.

IAR Systems and SiFive partner to meet customers’ demands for professional solutions for RISC-V

Establish partnership for delivering increased possibilities for powerful RISC-V implementationsRISC-V Summit, Santa Clara, California—December 3, 2018—IAR Systems®, the future-proof supplier of software tools and services for embedded development, and SiFive, the leading provider of commercial RISC-V processor IP, announce that they have formed a partnership in order to deliver increased possibilities for powerful RISC-V implementations with compact code and high performance. The RISC-V technology and ecosystem are evolving rapidly. With the rapid growth, the need for professional

There are no items matching the current filter
There are no more items matching the current filter
Back to top